Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Masahiro Tsuboi, MD, on Osimertinib as Adjuvant Treatment in EGFR-Mutated NSCLC

Posted: Sunday, September 20, 2020

Masahiro Tsuboi, MD, of Japan’s National Cancer Center Hospital East, discusses findings from the ADAURA study of patients with non–small cell lung cancer who are treated with osimertinib, suggesting it may be a feasible agent for adjuvant treatment in early-stage disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.